Foghorn Therapeutics, Inc. (FHTX)
2.085
0.00 (0.00%)
USD |
NASDAQ |
Oct 30, 16:00
2.085
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Cash from Operations (Quarterly) : -17.84M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -17.84M |
| March 31, 2026 | -25.27M |
| December 31, 2025 | -22.27M |
| September 30, 2025 | -18.86M |
| June 30, 2025 | -21.00M |
| March 31, 2025 | -23.97M |
| December 31, 2024 | -24.52M |
| September 30, 2024 | -21.00M |
| June 30, 2024 | -25.54M |
| March 31, 2024 | -29.34M |
| December 31, 2023 | -27.54M |
| September 30, 2023 | -27.21M |
| June 30, 2023 | -32.18M |
| Date | Value |
|---|---|
| March 31, 2023 | -31.18M |
| December 31, 2022 | -28.92M |
| September 30, 2022 | -19.99M |
| June 30, 2022 | -29.01M |
| March 31, 2022 | 271.53M |
| December 31, 2021 | 11.88M |
| September 30, 2021 | -20.50M |
| June 30, 2021 | -18.48M |
| March 31, 2021 | -23.15M |
| December 31, 2020 | -10.66M |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | -10.76M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | -9.096M |
| Vaxcyte, Inc. | -232.47M |
| Connect Biopharma Holdings Ltd. | -16.19M |
| Caribou Biosciences, Inc. | -22.79M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.967M |
| Cash from Financing (Quarterly) | -0.022M |
| Free Cash Flow | -84.29M |
| Free Cash Flow Per Share (Quarterly) | -0.2534 |
| Free Cash Flow to Equity (Quarterly) | -19.00M |
| Free Cash Flow to Firm (Quarterly) | -17.89M |
| Free Cash Flow Yield | -62.23% |